No profile data available.
Innoviva, Inc. (INVA) is a healthcare company in the lung treatment pharmaceuticals industry, based in Burlingame, United States, with about 159 full-time employees.
It reported revenue of $358.71 million for fiscal year 2024, up 15.5% from fiscal year 2023, and net income of $23.39 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $107.80 million, up 20.4% from a year before. Its market capitalization was $1.53 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Innoviva reported $358.71 million in revenue for fiscal year 2024, up 15.5% from $310.46 million in fiscal year 2023. In Q3 2025 revenue was $107.80 million.
$1.53 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (lung treatment pharmaceuticals) include Vertex Pharmaceuticals Incorporated (VRTX), Upstream Bio, Inc. (UPB), Savara Inc. (SVRA), Gyre Therapeutics, Inc. (GYRE).